Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
The drug being tested in this study is called alkotinib. Alkotinib has been demonstrated to benefit people with ALK+ NSCLC.
The study is a non-control study.
The study will enroll approximately 104 participants. All participants will take alkotinib 300mg throughout the study.
This multi-center trial will be conducted in China. The overall time to participate in this study is 3 years. Participants will make multiple visits to the site, and 28 days after last dose of study drug for a follow-up assessment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Evidence of positive ALK.
Patients must have demonstrated progression during or after crizotinib treatment.
Age 18 years or older at the time of informed consent.
Eastern cooperative oncology group performance status (ECOG PS) of 0-2
At least one measurable lesion by response evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1).
Willingness and ability to comply with the trial and follow-up procedures.
You may not be if
chemotherapy, radiation therapy, immunotherapy within 4 weeks.
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications.
Uncontrolled mass of pleural effusion, pericardial effusion, and peritoneal effusion
Clareo Health | Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
